Low Dose Hypersensitivity in the T98G Human Glioblastoma Cell Line
Overview
Authors
Affiliations
Purpose: To examine the low dose-response of a human radioresistant glioblastoma cell line (T98G) using two different methods to measure surviving fraction and to define the influence of cell cycle phase on this response.
Materials And Methods: The survival of cells following exposure to single very low doses of X-rays in vitro was measured using either the Dynamic Microscopic Image Processing Scanner (DMIPS) or a Cell Sorter (CS). The DMIPS was also used to measure the low dose survival response of T98G cells following manipulation of their progression through the cell cycle.
Results: With both methods, T98G demonstrated marked low dose hyper-radiosensitivity (HRS) and the two methods produced very similar data in the low dose region of the survival curve. However, the CS protocol produced less variable results and was the more efficient method of generating low dose data. HRS was also demonstrated when these cells were irradiated while held in reversible arrest in the G1 phase of the cell cycle, but the effect was less marked than in the asynchronous population.
Conclusions: T98G glioblastoma cells demonstrate marked HRS, which is a characteristic of the whole population rather than being due to the influence of a small subpopulation of hyper-radiosensitive cells within a particular phase of the cell cycle.
Opportunities and challenges in combining immunotherapy and radiotherapy in esophageal cancer.
Zhang X, Cai X, Yan C J Cancer Res Clin Oncol. 2023; 149(20):18253-18270.
PMID: 37985502 PMC: 10725359. DOI: 10.1007/s00432-023-05499-z.
Binelli L, Dini V, Amatori S, Scotognella T, Giordano A, De Berardis B Nanomaterials (Basel). 2023; 13(13).
PMID: 37446414 PMC: 10343762. DOI: 10.3390/nano13131898.
Polgar S, Schofield P, Madas B Sci Data. 2022; 9(1):555.
PMID: 36075916 PMC: 9458642. DOI: 10.1038/s41597-022-01653-3.
Koryakina E, Potetnya V, Troshina M, Baykuzina R, Koryakin S, Lychagin A Int J Mol Sci. 2022; 23(12).
PMID: 35743215 PMC: 9223725. DOI: 10.3390/ijms23126765.
Shang S, Liu J, Verma V, Wu M, Welsh J, Yu J Cancer Commun (Lond). 2021; 41(11):1086-1099.
PMID: 34658186 PMC: 8626591. DOI: 10.1002/cac2.12226.